ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

17 links6 made here, not in the record28 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older versionMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT05826964Levels of Circulating TumorDNA as a Predictive Markerfor Early Switch inTreatment for Patients WithMetastatic (Stage IV)Breast CancerUniversity of MiamiPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSAnastrozoleEntry “AI+CDK4/6i”, read by our name …›Nov 3 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionFulvestrantEntry “SERD+CDK4/6i”, read by our nam…›Nov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionEverolimusEntry “mTOR inhibitor + AI”, read by …›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundMTOR InhibitorEntry “mTOR inhibitor + Selective est…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSERMsEntry “mTOR inhibitor + Selective est…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAlpelisibEntry “PI3K inhibitor + SERD”, read b…›Nov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionINT007009Entry “Chemotherapy”, read by our nam…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedElacestrantEntry “Oral SERD”, read by our name r…›Nov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionINT017508Entry “PARPi”, read by our name rule›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedINT010053Entry “AKT inhibitor”, read by our na…›Nov 3 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedOlaparibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · BackgroundBackgroundPalbociclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · optionRibociclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · optionAbemaciclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · optionCapivasertibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · optionBackground · optionExemestaneMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · Background · optionBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Anastrozole

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “AI+CDK4/6i”the record gives no role
→judged→changed→changed
How the 3 judgments split33%of judgments with a known value say Background · option
Background · option · 1
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3Olaparibmade hereClaude Opus 5.5BackgroundCurrent
Nov 3Palbociclibmade hereClaude Opus 5.5Background · optionCurrent
Nov 3Ribociclibmade hereClaude Opus 5.5Background · optionCurrent
Nov 3Abemaciclibmade hereClaude Opus 5.5Background · optionCurrent
Nov 3AnastrozoleClaude Opus 5.5TestedReplaced
Nov 3FulvestrantClaude Opus 5.5Background · optionCurrent
Nov 3EverolimusClaude Opus 5.5BackgroundCurrent
Nov 3MTOR InhibitorClaude Opus 5.5TestedCurrent
Nov 3SERMsClaude Opus 5.5TestedCurrent
Nov 3AlpelisibClaude Opus 5.5Background · optionCurrent
Nov 3INT007009Claude Opus 5.5TestedCurrent
Nov 3ElacestrantClaude Opus 5.5Background · optionCurrent
Nov 3INT017508Claude Opus 5.5TestedCurrent
Nov 3INT010053Claude Opus 5.5TestedCurrent
Nov 3Capivasertibmade hereClaude Opus 5.5Background · optionCurrent
Nov 10AnastrozoleClaude Opus 5.5Background · optionCurrent
Nov 10Exemestanemade hereClaude Opus 5.5Background · optionCurrent
Nov 18The record itselfClinicalTrials.gov recordVersion of 2026-11-18Record change
Nov 18AnastrozoleRule based · role ruleTestedOverridden
Nov 18FulvestrantRule based · role ruleTestedOverridden
Nov 18EverolimusRule based · role ruleBackgroundAgrees
Nov 18MTOR InhibitorRule based · role ruleTestedAgrees
Nov 18SERMsRule based · role ruleTestedAgrees
Nov 18AlpelisibRule based · role ruleBackgroundAgrees
Nov 18INT007009Rule based · role ruleTestedAgrees
Nov 18ElacestrantRule based · role ruleBackgroundAgrees
Nov 18INT017508Rule based · role ruleTestedAgrees
Nov 18INT010053Rule based · role ruleTestedAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.